Long-Term Outcomes of Drug-Refractory Atrial Fibrillation After Atrioventricular Node Ablation Combined with Implantation of a Cardiac Resynchronization Therapy Defibrillator (CRT-D).
Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial.
Merkely B, Hatala R, Wranicz JK, Duray G, Földesi C, Som Z, Németh M, Goscinska-Bis K, Gellér L, Zima E, Osztheimer I, Molnár L, Karády J, Hindricks G, Goldenberg I, Klein H, Szigeti M, Solomon SD, Kutyifa V, Kovács A, Kosztin A.
Eur Heart J. 2023 Oct 21;44(40):4259-4269. doi: 10.1093/eurheartj/ehad591.
Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project.
Hadwiger M, Dagres N, Haug J, Wolf M, Marschall U, Tijssen J, Katalinic A, Frielitz FS, Hindricks G.
Eur Heart J. 2022 Jul 14;43(27):2591-2599. doi: 10.1093/eurheartj/ehac053.
Follow-up and characteristics of recipients of cardiac resynchronization therapy with and without a defibrillator.
Grymuza M, Katarzyńska-Szymańska A, Chmielewska-Michalak L, Waśniewski M, Ochotny R, Lesiak M, Mitkowski P.
Kardiol Pol. 2022;80(7-8):806-812. doi: 10.33963/KP.a2022.0125. Epub 2022 May 12.
Cardiac Resynchronization Therapy with Defibrillator in Ischemic Versus Nonischemic Cardiomyopathy.
Yuecel G, Gaasch L, Hetjens S, Oeztuerk ON, Yildirim G, Pfleger S, Duerschmied D, Akin I, Kuschyk J.
Int Heart J. 2024;65(5):823-832. doi: 10.1536/ihj.24-023.
The benefits of defibrillator in heart failure patients with cardiac resynchronization therapy: A meta-analysis.
Long YX, Hu Y, Cui DY, Hu S, Liu ZZ.
Pacing Clin Electrophysiol. 2021 Feb;44(2):225-234. doi: 10.1111/pace.14150. Epub 2021 Jan 5.
Effectiveness of adding a defibrillator with cardiac resynchronization therapy in heart failure according to the modified Model for End-stage Liver Disease-Albumin score.
Cheng S, Deng Y, Huang H, Yu Y, Niu H, Hua W.
Europace. 2023 Aug 2;25(9):euad232. doi: 10.1093/europace/euad232.
Cardiac Resynchronization Therapy With or Without Defibrillation: A Long-Standing Debate.
Golzio PG, Bocchino PP, Bissolino A, Angelini F, Gravinese C, Frea S.
Cardiol Rev. 2022 Sep-Oct 01;30(5):221-233. doi: 10.1097/CRD.0000000000000388. Epub 2021 Mar 19.
Variation in hospital use of cardiac resynchronization therapy-defibrillator among eligible patients and association with clinical outcomes.
Chui PW, Lan Z, Freeman JV, Enriquez AD, Khera R, Akar JG, Masoudi FA, Ong EL, Curtis JP.
Heart Rhythm. 2023 Jul;20(7):1000-1008. doi: 10.1016/j.hrthm.2023.03.022. Epub 2023 Mar 22.
Time-trend treatment effect of cardiac resynchronization therapy with or without defibrillator on mortality: a systematic review and meta-analysis.
Veres B, Fehérvári P, Engh MA, Hegyi P, Gharehdaghi S, Zima E, Duray G, Merkely B, Kosztin A.
Europace. 2023 Oct 5;25(10):euad289. doi: 10.1093/europace/euad289.
Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C, Paolisso P, Sacra C, Santamaria M, de Lucia C, Ruocco A, Mauro C, Paolisso G, Rizzo MR, Barbieri M, Marfella R.
Cardiovasc Diabetol. 2018 Oct 22;17(1):137. doi: 10.1186/s12933-018-0778-9.
